Detalles de la búsqueda
1.
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol
; 204(3): 861-870, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37939390
2.
Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study.
Br J Haematol
; 204(6): 2342-2350, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400570
3.
Thiotepa-busulfan-fludarabine-based conditioning as a promising approach prior to allogeneic hematopoietic stem cell transplantation in patients with blastic plasmacytoid dendritic cell neoplasm.
Ann Hematol
; 103(6): 2165-2168, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38584216
4.
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Br J Haematol
; 202(6): 1119-1126, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37434414
5.
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis.
Ann Hematol
; 102(9): 2387-2395, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278748
6.
A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia.
Support Care Cancer
; 30(8): 7031-7038, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35585204
7.
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia.
Br J Haematol
; 193(6): 1096-1104, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33764511
8.
CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
Am J Hematol
; 96(3): 312-319, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306218
9.
Overcoming right heart failure through successful treatment of cardiac dominant diffuse large B-cell lymphoma: a case report.
Ann Hematol
; 103(1): 343-345, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37736807
10.
The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Ann Hematol
; 101(5): 1141-1144, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34661714
11.
An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol
; 189(6): e231-e234, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32314800
12.
Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
Am J Hematol
; 95(3): E55-E57, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31907961
13.
[Bortezomib-induced peripheral neuropathy in multiple myeloma patients].
Zhonghua Yi Xue Za Zhi
; 95(40): 3297-301, 2015 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-26815352
14.
Effective management of a rare case of primary renal intravascular large B-cell lymphoma with modified R-CHOP regimen: A case report.
SAGE Open Med Case Rep
; 12: 2050313X241232259, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38362227
15.
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Ann Hematol
; 92(8): 1091-100, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23595277
16.
Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.
Biomark Res
; 11(1): 105, 2023 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38053201
17.
Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center.
Exp Hematol Oncol
; 11(1): 57, 2022 Sep 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36114573
18.
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
J Hematol Oncol
; 15(1): 148, 2022 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36258250
19.
Not BCL2 mutation but dominant mutation conversation contributed to acquired venetoclax resistance in acute myeloid leukemia.
Biomark Res
; 9(1): 30, 2021 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33933163
20.
Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia.
Front Oncol
; 10: 1423, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32974153